Evidence map›Paper›PMID 41835391›Full record

ArticlebioRxiv : the preprint server for biology2026

Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory.

Zehra E F Demir, AeRyon Kim, Beyzanur G Ak, Micaiah S J Lee, Thomas Sherlock, Stefanyda O Maslova, Andrew T Thede, Matthew R DeWitt, Melanie R Rutkowski, Natasha D Sheybani

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Zehra E F DemirDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
AeRyon KimDepartment of Pathology, University of Virginia, Charlottesville, VA.
Beyzanur G AkDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Micaiah S J LeeDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Thomas SherlockDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Stefanyda O MaslovaDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Andrew T ThedeDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Matthew R DeWittDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Melanie R RutkowskiDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA.
Natasha D SheybaniDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.ORCID 0000-0002-1137-058X

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Immunoengineering Next-Generation Cancer Therapies with Focused UltrasoundDP5OD031846 · OD · UNIVERSITY OF VIRGINIA · PI SHEYBANI, NATASHA DIBA · 2021 to 2025
$2.0M
NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA009109NIH HHS DP5 OD031846
6 · The paper itself

Abstract

Focused ultrasound thermal ablation (T-FUS) is a clinically accessible, non-invasive modality capable of inducing rapid tumor cytoreduction while mobilizing early immunologic danger signals. However, its capacity to synergize with potent co-stimulatory immunotherapies in breast cancer (BC) remains undefined. Here, we demonstrate that subtotal T-FUS cooperates with CD40 agonism to elicit durable, T cell-dependent tumor control across four immunologically and hormonally distinct murine BC models. Partial thermal ablation triggered canonical immunogenic cell-death signatures and acute remodeling of intratumoral myeloid populations, while expanding circulating CD4

Identifiers

PMID41835391
PMCPMC12980387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.